Charcot-Marie-Tooth Disease, Type IA Clinical Trial
— BALTiCOfficial title:
BALTiC Study: A Feasibility Analysis of Home Based BALance Training in People With Charcot-Marie-Tooth Disease
NCT number | NCT02982343 |
Other study ID # | 16/LO/0720 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | December 2016 |
Est. completion date | March 2018 |
Verified date | May 2018 |
Source | University College London Hospitals |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Charcot Marie Tooth (CMT) is the most common inherited neuropathy. It affects the nerves of the hands and feet first, slowly progressing towards the centre of the body. It causes varying degrees of weakness and reduced feeling, usually affecting the feet and ankles first. High incidence of falls and knock on effects in quality of life are common. This is a lifelong condition which, though not life limiting, does not have a cure. Research into the effect of balance rehabilitation in people with CMT has been limited to traditional exercises, which do not address the complex nature of balance impairments in this condition. Multi-sensory rehabilitation has proved beneficial in improving balance in people with sensory neuropathy. Research shows that strengthening trunk muscles can improve balance in older people. Trunk and muscles close to it are largely unaffected in people with CMT, therefore these muscles could be strengthened in these patients. This study proposes to assess the feasibility of multi-sensory balance training, strength training with a focus on the trunk and muscles close to the trunk, and falls management education. This comprehensive approach is reflective of a clinical physiotherapy programme. Though a life-long condition, many people with CMT lead full lives. A home based programme is proposed to so that patients can fit it into their lives without having to travel for treatment. Therapists will use self-management principles within treatment. Measurements will be taken prior to and following treatment including physical measures, questionnaires and interviews. The physiotherapy interventions will be taught home and data collection will be at the National Hospital for Neurology and Neurosurgery, University College London Hospitals (UCLH).
Status | Completed |
Enrollment | 16 |
Est. completion date | March 2018 |
Est. primary completion date | March 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Genetically confirmed diagnosis of CMT1a 2. History of falls 3. Mixed sensory and motor presentation 4. Over 18 years 5. Able to stand unsupported for five minutes 6. Able to walk for 50m with or without a walking stick or orthotic devices Exclusion Criteria: 1. Presence of other significant neurological disorders (such as multiple sclerosis, cerebrovascular diseases, epilepsy, movement disorders), or major comorbidities (e.g. vestibular dysfunction, use of medication which may affect balance, cognitive impairment, presence of medical conditions in which exercise training may be detrimental). 2. Presence of peripheral neuropathy caused by a condition other then CMT. 3. Limb surgery during the six months prior to screening (or planned before final assessment). 4. Participation in any other concurrent intervention trial, or less than six months after cessation of an intervention trial. 5. Women of child-bearing age if they are pregnant, planning a pregnancy during their time in the study or in the 12 weeks following giving birth. This is due to the effects of pregnancy on balance. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | National Hospital for Neurology and Neurosurgery, UCLH | London |
Lead Sponsor | Collaborator |
---|---|
University College London Hospitals | Charcot Marie Tooth United Kingdom, Kingston University |
United Kingdom,
Chetlin RD, Gutmann L, Tarnopolsky M, Ullrich IH, Yeater RA. Resistance training effectiveness in patients with Charcot-Marie-Tooth disease: recommendations for exercise prescription. Arch Phys Med Rehabil. 2004 Aug;85(8):1217-23. — View Citation
Lindeman E, Leffers P, Spaans F, Drukker J, Reulen J, Kerckhoffs M, Köke A. Strength training in patients with myotonic dystrophy and hereditary motor and sensory neuropathy: a randomized clinical trial. Arch Phys Med Rehabil. 1995 Jul;76(7):612-20. — View Citation
Matjacic Z, Zupan A. Effects of dynamic balance training during standing and stepping in patients with hereditary sensory motor neuropathy. Disabil Rehabil. 2006 Dec 15;28(23):1455-9. — View Citation
Ramdharry GM, Pollard A, Anderson C, Laurá M, Murphy SM, Dudziec M, Dewar EL, Hutton E, Grant R, Reilly MM. A pilot study of proximal strength training in Charcot-Marie-Tooth disease. J Peripher Nerv Syst. 2014 Dec;19(4):328-32. doi: 10.1111/jns.12100. — View Citation
Ramdharry, G., M. Dudziec, D. Tropman, E. Dewar, A. Wallace, M. Laura, R. Grant, and M. Reilly. 2015. 'Exploring the Causes of Falls and Balance Impairments in People with Charcot-Marie Tooth Disease'. Physiotherapy 101 (May): e1255. doi:10.1016/j.physio.2015.03.1159.
van der Linden MH, van der Linden SC, Hendricks HT, van Engelen BG, Geurts AC. Postural instability in Charcot-Marie-Tooth type 1A patients is strongly associated with reduced somatosensation. Gait Posture. 2010 Apr;31(4):483-8. doi: 10.1016/j.gaitpost.2010.02.005. Epub 2010 Mar 11. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Balance performance | Balance performance will be measured using laboratory measures of postural stability during static and dynamic tasks. Centre of pressure excursion and velocity will be the main variables | 12 weeks | |
Secondary | Recruitment rate | For this feasibility study, recruitment rate data will be gathered | 1 year | |
Secondary | Falls monitoring | Falls monitoring will be done one month before, during the 12 week invention/control period and one month afterwards using postcards or a web based app, depending on participant preference. | 20 weeks | |
Secondary | Bruininks Oseretsky Test (BOT) | Clinician rated measure of functional balance performance. | 12 weeks | |
Secondary | Berg Balance test | Clinician rated measure of functional balance performance. | 12 weeks | |
Secondary | BESTest | Clinician rated measure of functional balance performance. | 12 weeks | |
Secondary | 10 minute timed walk | Walking speed test | 12 weeks | |
Secondary | Quantitative lower limb muscle strength testing | Hand-held myometry protocol performed by rater for the major lower limb muscle groups. | 12 weeks | |
Secondary | CMTES: Charcot Marie Tooth Examination Score | Clinician rated disease severity scale | 12 weeks | |
Secondary | Falls Self Efficacy Scale | Patient reported outcome measure of balance confidence. Questionnaire. | 12 weeks | |
Secondary | Walk-12 | Patient reported outcome measure of walking function. Questionnaire. | 12 weeks | |
Secondary | IPAQ: International Physical Activity Questionnaire | Patient reported outcome measure of physical activity. Questionnaire. | 12 weeks | |
Secondary | SF36: Short Form 36 | Patient reported outcome measure of health related quality of life. Questionnaire. | 12 weeks | |
Secondary | Hospital Anxiety and Depression Score | Patient reported outcome measure of depression and anxiety symptoms. Questionnaire. | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03550300 -
Muscle MRI in Charcot Mary Tooth Disease: a Prospective Cohort Study
|
||
Recruiting |
NCT05902351 -
Natural History Study for Charcot Marie Tooth Disease
|
||
Active, not recruiting |
NCT03023540 -
Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A
|
Phase 3 | |
Completed |
NCT05333406 -
Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A
|
Phase 1 | |
Completed |
NCT03386266 -
Biomarkers and Validation of Selected Outcome Measures (CMTNSmod)
|
||
Not yet recruiting |
NCT03397303 -
Quantification of Nerve Stiffness in Neuropathies
|
N/A | |
Completed |
NCT00484510 -
High Dose Ascorbic Acid Treatment of CMT1A
|
Phase 2/Phase 3 |